Evidence map›Paper›PMID 36701590›Full record

ReviewDiabetes care2023

The National Clinical Care Commission Report to Congress: Leveraging Federal Policies and Programs to Prevent Diabetes in People With Prediabetes.

John M Boltri, Howard Tracer, David Strogatz, Shannon Idzik, Pat Schumacher, Naomi Fukagawa, Ellen Leake, Clydette Powell, Donald Shell, Samuel Wu and 1 more

Open access · bronzeAbstract readReview
In one paragraph

Review in Diabetes care, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed, 1 pooled it
5.6field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 1 synthesis or guideline pooled it, 28 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
  4. Article
  5. Article
  6. Observational
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Review
  14. Review
  15. Article
  16. Rethinking diabetes in the United States.Frontiers in endocrinology · 2023
    Article
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 10 institutions in 1 country.

John M BoltriNortheast Ohio Medical University, Rootstown, OH.
Howard TracerAgency for Healthcare Research and Quality, Department of Health and Human Services, Rockville, MD.
David StrogatzBassett Healthcare Network, Cooperstown, NY.
Shannon IdzikSchool of Nursing, University of Maryland, Baltimore, MD.
Pat SchumacherCenters for Disease Control and Prevention, Department of Health and Human Services, Atlanta, GA.
Naomi FukagawaU.S. Department of Agriculture, Washington, DC.
Ellen LeakeJuvenile Diabetes Research Foundation, Jackson, MS.
Clydette PowellSchool of Medicine and Health Services, George Washington University, Washington, DC.
Donald ShellU.S. Department of Defense, Washington, DC.
Samuel WuU.S. Office of Minority Health, Rockville, MD.
William H HermanUniversity of Michigan, Ann Arbor, MI.ORCID 0000-0002-0502-674X
Agency for Healthcare Research and Quality · USBassett Healthcare Network · USBreakthrough T1D · USCenters for Disease Control and Prevention · USGeorge Washington University · USNortheast Ohio Medical University · USOffice of Minority Health · USUnited States Department of Defense · USUniversity of Maryland, Baltimore · USUniversity of Michigan · US

Funding

Regional Pilot And Feasibility Study Grants ProgramP30DK020572 · NIDDK · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI DAVID P OLSON · 2013 to 2026
$24.3M
Research BaseP30DK092926 · NIDDK · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI MARY ELLEN MICHELE HEISLER, ADESUWA B OLOMU · 2011 to 2026
$10.0M
NIDDK NIH HHS P30 DK020572NIDDK NIH HHS P30 DK092926
6 · The paper itself

Abstract

Individuals with an elevated fasting glucose level, elevated glucose level after glucose challenge, or elevated hemoglobin A1c level below the diagnostic threshold for diabetes (collectively termed prediabetes) are at increased risk for type 2 diabetes. More than one-third of U.S. adults have prediabetes but fewer than one in five are aware of the diagnosis. Rigorous scientific research has demonstrated the efficacy of both intensive lifestyle interventions and metformin in delaying or preventing progression from prediabetes to type 2 diabetes. The National Clinical Care Commission (NCCC) was a federal advisory committee charged with evaluating and making recommendations to improve federal programs related to the prevention of diabetes and its complications. In this article, we describe the recommendations of an NCCC subcommittee that focused primarily on prevention of type 2 diabetes in people with prediabetes. These recommendations aim to improve current federal diabetes prevention activities by 1) increasing awareness of and diagnosis of prediabetes on a population basis; 2) increasing the availability of, referral to, and insurance coverage for the National Diabetes Prevention Program and the Medicare Diabetes Prevention Program; 3) facilitating Food and Drug Administration review and approval of metformin for diabetes prevention; and 4) supporting research to enhance the effectiveness of diabetes prevention. Cognizant of the burden of type 1 diabetes, the recommendations also highlight the importance of research to advance our understanding of the etiology of and opportunities for prevention of type 1 diabetes.

Indexed as

Diabetes Mellitus, Type 1Diabetes Mellitus, Type 2MetforminPrediabetic StateAdultAgedGlucoseHumansMedicareUnited StatesGlucoseMetformin

Identifiers

PMID36701590
PMCPMC9887613
OpenAlexW4318162979

What Socratic holds

Texttitle and abstract
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.